MedPath

UNIVERSITY OF EXETER

🇪🇸Spain
Ownership
-
Established
1955-01-01
Employees
-
Market Cap
-
Website
https://www.exeter.ac.uk/

Clinical Trials

132

Active:7
Completed:86

Trial Phases

5 Phases

Phase 1:1
Phase 2:1
Phase 3:1
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (99 trials with phase data)• Click on a phase to view related trials

Not Applicable
95 (96.0%)
Phase 1
1 (1.0%)
Phase 2
1 (1.0%)
Phase 3
1 (1.0%)
Phase 4
1 (1.0%)

Zithandani Stepping Stones and Creating Futures - Phase 2 Pilot

Not Applicable
Not yet recruiting
Conditions
Intimate Partner Violence (IPV)
Earning Outcomes
Mental Health
Couple Communication
Couple Conflict
Couples
Livelihoods
First Posted Date
2025-05-16
Last Posted Date
2025-05-20
Lead Sponsor
University of Exeter
Target Recruit Count
100
Registration Number
NCT06975137
Locations
🇿🇦

South African Medical Research Council, Durban, South Africa

The Effect of a Plant-based, Protein-dense Sauce on Essential Amino Acid Concentrations and Gut Fullness in Older Adults

Not Applicable
Not yet recruiting
Conditions
Malnutrition Elderly
Protein Malnutrition
First Posted Date
2025-05-11
Last Posted Date
2025-05-11
Lead Sponsor
University of Exeter
Target Recruit Count
20
Registration Number
NCT06965699
Locations
🇬🇧

University of Exeter, Exeter, Devon, United Kingdom

Development of a Novel Screening Tool for Anosognosia After Stroke.

Not yet recruiting
Conditions
Anosognosia
Stroke
First Posted Date
2025-04-23
Last Posted Date
2025-04-27
Lead Sponsor
University of Exeter
Target Recruit Count
90
Registration Number
NCT06940882

Short-term Effect of Using Non-immersive Gamified Exercises on Chronic Pain in People With Stroke.

Recruiting
Conditions
Stroke Patients
First Posted Date
2025-03-07
Last Posted Date
2025-04-16
Lead Sponsor
University of Exeter
Target Recruit Count
30
Registration Number
NCT06863649
Locations
🇬🇧

Vsimulator, Exeter, Devon, United Kingdom

The Effect of Ingesting a Novel Algae Protein Source on Rested and Exercised Muscle Protein Synthesis Rates in Older Adults.

Not Applicable
Recruiting
Conditions
Nutritional Intervention
First Posted Date
2025-02-28
Last Posted Date
2025-02-28
Lead Sponsor
University of Exeter
Target Recruit Count
15
Registration Number
NCT06852547
Locations
🇬🇧

Health and Life Sciences, Exeter, United Kingdom

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 26
  • Next

News

Mindfulness-Based Cognitive Therapy Shows Promise for Treatment-Resistant Depression

A new clinical trial published in Lancet Psychiatry demonstrates that mindfulness-based cognitive therapy (MBCT) significantly improves symptoms in patients with difficult-to-treat depression compared to standard care.

Medicines Discovery Catapult Expands Strategic Partnerships to Accelerate UK Drug Discovery Innovation

Medicines Discovery Catapult has formed two major strategic partnerships with the Francis Crick Institute and University of Exeter to accelerate drug discovery and translational research across the UK.

Anti-Inflammatory Drugs and Infection Control May Reduce Dementia Risk, Studies Suggest

Recent evidence reviews indicate that controlling infections through vaccines, antibiotics, and antivirals may significantly reduce dementia risk, supporting theories linking infectious causes to common dementias.

UK Launches First Anti-Viral Drug Trial for Long COVID Treatment

Researchers from the University of Derby and Plymouth have initiated the UK's first anti-viral drug trial for long COVID, testing medication previously used only for hospitalized COVID-19 patients.

Phase 2 Trial Assesses 99mTc-maraciclatide for ILD Prognosis

A Phase 2 study, PREDICT-ILD, has commenced to evaluate 99mTc-maraciclatide, a novel molecular imaging agent, for predicting interstitial lung disease (ILD) progression.

© Copyright 2025. All Rights Reserved by MedPath